Kajalakshmy M. “Phase Ii Trial Of Bevacizumab, Irinotecan, And Cetuximab In Recurrent Glioblastoma Multiforme: Efficacy, Safety And Clinical Outcomes”. Journal for ReAttach Therapy and Developmental Diversities, vol. 5, no. 2, Dec. 2022, pp. 788-92, doi:10.53555/jrtdd.v5i2.3854.